Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-04-14 00:00:00 ET · period of report 2022-04-13 · accession 0000899243-22-014805 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-14 | 2022-04-13 | VRTX | LEIDEN JEFFREY M | Executive COB, Dir | S - Sale | $289.04 | -15.8K | 74.2K | -18% | -$4.56M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-13 | S | D | 15,789 | $289.04 | 74,160 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $289.04 (range $289.00 to $289.58). (F2) Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |